Bausch Health Companies Inc. Depreciation
Bausch Health Companies Inc. (BHC) reported Depreciation of $207.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-19
- Bausch Health Companies Inc. depreciation for fiscal 2025 was $207.00M, a 8.95% increase from fiscal 2024.
- Bausch Health Companies Inc. depreciation for fiscal 2024 was $190.00M, a 1.60% increase from fiscal 2023.
- Bausch Health Companies Inc. depreciation for fiscal 2023 was $187.00M, a 4.47% increase from fiscal 2022.
- Bausch Health Companies Inc. depreciation for fiscal 2022 was $179.00M, a 1.13% increase from fiscal 2021.
| Period end | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|
| 2025-12-31 | $207.00M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $190.00M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $187.00M 10-K · filed 2026-02-19 | |
| 2022-12-31 | $179.00M 10-K · filed 2025-02-20 | |
| 2021-12-31 | $177.00M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $180.00M 10-K · filed 2023-02-23 | |
| 2019-12-31 | $178.00M 8-K · filed 2022-05-11 | |
| 2018-12-31 | $175.00M 8-K · filed 2021-05-04 | |
| 2017-12-31 | $168.00M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $193.00M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $210.00M 8-K · filed 2018-08-10 | $209.00M 10-K · filed 2016-04-29 |
| 2014-12-31 | $187.00M 10-K · filed 2017-03-01 | $186.90M 10-K · filed 2015-02-25 |
| 2013-12-31 | $114.00M 10-K · filed 2016-04-29 | $113.80M 10-K · filed 2014-02-28 |
| 2012-12-31 | $54.80M 10-K · filed 2015-02-25 | |
| 2011-12-31 | $45.60M 10-K · filed 2014-02-28 | |
| 2010-12-31 | $23.90M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $18.80M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |